Inactive Instrument

Press Releases Momenta Pharmaceuticals, Inc.

Equities

MNTA

US60877T1007

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Johnson & Johnson : Completes Acquisition of Momenta Pharmaceuticals, Inc.; Acquisition broadens Janssen's leadership in autoimmune diseases and provides a major catalyst for sustained growth	20-10-05	AQ
Momenta Pharmaceuticals : Announces Completion of Proposed Sale to Johnson & Johnson	20-10-02	AQ
Johnson & Johnson : Completes Acquisition of Momenta Pharmaceuticals, Inc.	20-10-02	AQ
MOMENTA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-10-01	AQ
Momenta Pharmaceuticals : Announces Completion of Proposed Sale to Johnson & Johnson	20-10-01	AQ
Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson	20-10-01	GL
Momenta Pharmaceuticals : Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	20-09-16	AQ
Momenta Pharmaceuticals : Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	20-09-15	AQ
Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson	20-09-15	GL
MOMENTA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Momenta Pharmaceuticals, Inc. - MNTA	20-08-20	BU
Johnson & Johnson : Target, Momenta Pharmaceuticals rise; BioMarin, TJX fall	20-08-19	AQ
MOMENTA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	20-08-19	AQ
Momenta Pharmaceuticals : Enters Definitive Agreement with Johnson & Johnson	20-08-19	AQ
Momenta Enters Definitive Agreement with Johnson & Johnson	20-08-19	GL
MOMENTA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	20-08-10	AQ
Momenta: 2Q Earnings Snapshot	20-08-10	AQ
Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results	20-08-10	GL
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast	20-08-03	GL
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN	20-07-28	GL
MOMENTA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	20-06-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Momenta Pharmaceuticals, Inc.

Equities

MNTA

US60877T1007

Press Releases

Filters